Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Liabilities and Shareholders Equity (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Liabilities and Shareholders Equity readings, the most recent being $225.6 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 176.32% to $225.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $517.8 million through Mar 2026, up 31.24% year-over-year, with the annual reading at $150.9 million for FY2025, 63.76% up from the prior year.
  • Liabilities and Shareholders Equity hit $225.6 million in Q1 2026 for Ovid Therapeutics, up from $150.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $225.6 million in Q1 2026 and bottomed at $63.8 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $134.2 million, with a median of $136.2 million recorded in 2023.
  • The largest annual shift saw Liabilities and Shareholders Equity crashed 37.96% in 2025 before it surged 176.32% in 2026.
  • Ovid Therapeutics' Liabilities and Shareholders Equity stood at $155.3 million in 2022, then fell by 7.24% to $144.0 million in 2023, then crashed by 36.01% to $92.2 million in 2024, then surged by 63.76% to $150.9 million in 2025, then soared by 49.49% to $225.6 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Liabilities and Shareholders Equity are $225.6 million (Q1 2026), $150.9 million (Q4 2025), and $63.8 million (Q3 2025).